Trazodone hydrochloride 50 mg capsule, hard

Strides Pharma UK Ltd🇬🇧 Electronic Medicines Compendium

Approval Date: N/A
Approval ID: 57b87cd547aa01a5
Company: Strides Pharma UK Ltd
Type: Standard

Approval Details

Approval Id: 57b87cd547aa01a5
Drug Approval Emc Name: Trazodone hydrochloride 50 mg capsule, hard
Drug Name: Trazodone hydrochloride 50 mg capsule, hard
Company Name: Strides Pharma UK Ltd
Company Address: Unit 4, Metro Centre, Tolpits Lane, Watford, Hertfordshire, UK
Company Website: //www.stridespharma.co.uk
Company Telephone: +44 1923 255580
Company Medical Info Direct Line: +44 8000 988 048
Company Medical Info Email: drugsafety@strides.com
Atc Code: N06AX05
Legal Category: Prescription only medicine
Authorisation Holder: Strides Pharma UK Ltd Unit 4, The Metro Centre Dwight Road, Watford WD18 9SS United Kingdom
Authorisation Number: PL 13606/0240
Authorisation Date: 23/01/2019
Instruction Authorisation Holder: Strides Pharma UK Ltd Unit 4, The Metro Centre Dwight Road, Watford WD18 9SS United Kingdom
Instruction Authorisation Number: PL 13606/0240
Instruction Authorisation Date: 23/01/2019
Instruction Composition: Each capsule, hard contains 50 mg trazodone hydrochloride. Excipients with known effect Each capsule, hard contains 73.75 mg of lactose monohydrate. Each capsule, hard contains 0.0094 mg of carmoisine. For the full list of excipients, see section 6.1.
Instruction Dosage Form: Capsule, hard (capsule) White to off white granular powder filled in size “3” hard gelatin capsule with violet color cap and green color body printed 'TZ' on cap and '50' on body in black.
Instruction Clinical Particulars: 4.1 Therapeutic indications Anxiety, depression, mixed anxiety and depression.4.2 Posology and method of administration Posology Depression \*Adults\* Initially 150 mg/day in divided doses after food or as a single dose on retiring. This may be increased up to 300 mg/day in a single or divided doses. The major portion of a divided dose to be taken on retiring. The dose may be further increased to 600 mg/day in divided doses in hospitalised patients. \*Elderly\* For very elderly or frail patients, the recommended initial starting dose is reduced to 100 mg/day given in divided doses or as a single night-time dose (see section 4.4). This may be incrementally increased, under supervision, according to efficacy and tolerance. In general, single doses above 100 mg should be avoided in these patients. It is unlikely that 300 mg/day will be exceeded. \*Paediatric population\* There are insufficient data on safety to recommend the use of trazodone capsules in children below the age of 18 years. Depression accompanied by anxiety As for depression Anxiety 75 mg/day increasing to 300 mg/day as necessary. \*Hepatic Impairment\* Trazodone undergoes extensive hepatic metabolism, see section 5.2, and has also been associated with hepatotoxicity, see sections 4.4 and 4.8. Therefore caution should be exercised when prescribing for patients with hepatic impairment, particularly in cases of severe hepatic impairment. Periodic monitoring of liver function may be considered. \*Renal Impairment\* No dosage adjustment is usually necessary, but caution should be exercised when prescribing for patients with severe renal impairment (see also section 4.4 and 5.2). Method of administration For oral use. A decrease in side-effects (increase of the resorption and decrease of the peak plasma concentration) can be reached by taking trazodone capsules after a meal.4.3 Contraindications • Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. • Alcohol intoxication and intoxication with hypnotics. • Acute myocardial infarction.4.4 Special warnings and precautions for use Paediatric population Trazodone capsules should not be used in children and adolescents under 18 years old. Suicidal behaviour (suicidal attempt and suicidal planning) and hostility (essentially aggressiveness, opposing behaviour and anger) has been observed in a clinical study on children and adolescents treated with antidepressant more frequently than with placebo. Moreover, long-term safety data on children and adolescents regarding growth, maturation and cognitive and behavioural development are not available. Suicide/suicidal thoughts or clinical worsening Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide- related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Other psychiatric conditions for which trazodone capsules is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders. Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo- controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present. To minimise the potential risk of suicide attempts, particularly at therapy initiation, only restricted quantities of trazodone capsules should be prescribed at each occasion. It is recommended that careful dosing and regular monitoring is adopted in patients with the following conditions: • Epilepsy, specifically abrupt increases or decreases of dosage should be avoided. • Patients with hepatic or renal impairment, particularly if severe. • Patients with cardiac disease, such as angina pectoris, conduction disorders or AV blocks of different degree, recent myocardial infarction. • Hyperthyroidism. • Micturition disorders, such as prostate hypertrophy, although problems would not be anticipated as the anticholinergic effect of trazodone capsules is only minor. • Acute narrow angle glaucoma, raised intra-ocular pressure, although major changes would not be anticipated due to the minor anticholinergic effect of trazodone capsules. Should jaundice occur in a patient, trazodone therapy must be withdrawn. Hepatic disorders Severe hepatic disorders with potential fatal outcome have been reported with trazodone use (see adverse reaction section). Patients should be instructed to immediately report signs such as asthenia, anorexia, nausea, vomiting, abdominal pain or icterus to a physician. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately, and withdrawal of trazodone therapy be considered. Schizophrenia and other psychotic disorders Administration of antidepressants in patients with schizophrenia or other psychotic disorders may result in a possible worsening of psychotic symptoms. Paranoid thoughts may be intensified. During trazodone therapy a depressive phase can change from a manic–depressive psychosis into a manic phase. In that case trazodone capsules must be stopped. Serotonin Syndrome / Malignant Neuroleptic Syndrome Interactions in terms of serotonin syndrome/malignant neuroleptic syndrome have been described in case of concomitant use of other serotonergically acting substances like other antidepressants (e.g., tricyclic antidepressants, SSRIs, SNRIs and MAO-inhibitors) and neuroleptics. Malignant neuroleptic syndromes with fatal outcome have been reported in cases of co-administration with neuroleptics, for which this syndrome is a known possible adverse drug reaction. See sections 4.5 and 4.8 for further information. \*Serotonin syndrome\* Concomitant administration of trazodone and \*\*buprenorphine/opioids may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5).\*\* If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms. Agranulocytosis Since agranulocytosis may clinically reveal itself with influenza-like symptoms, sore throat, and fever, in these cases it is recommended to check haematology. Hypotension Hypotension, including orthostatic hypotension and syncope, has been reported to occur in patients receiving trazodone capsules. Concomitant administration of antihypertensive therapy with trazodone capsules may require a reduction in the dose of the antihypertensive drug. Elderly population Elderly patients may more often experience orthostatic hypotension, somnolence and other anticholinergic effects of trazodone. Careful consideration should be given to the potential for additive effects with concomitant medication use such as with other psychotropics or antihypertensives or in the presence of risk factors such as comorbid disease, which may exacerbate these reactions. It is recommended that the patient/carer be informed of the potential for these reactions and monitored closely for such effects following initiation of therapy, prior to and following upward dose titration. Withdrawal symptoms Following trazodone therapy, particularly for a prolonged period, an incremental dosage reduction to withdrawal is recommended, to minimise the occurrence of withdrawal symptoms, characterised by nausea, headache, and malaise. There is no evidence that trazodone capsules possesses any addictive properties. QT prolongation As with other antidepressant drugs, cases of QT interval prolongation have been reported with trazodone capsules very rarely. Caution is advised when prescribing trazodone capsules with medicinal products known to prolong QT interval. Trazodone capsules should be used with caution in patients with known cardiovascular disease including those associated with prolongation of the QT interval. CYP3A4 inhibitors Potent CYP3A4 inhibitors may lead to increases in trazodone serum levels. See section 4.5 for further information. Priapism As with other drugs with alpha-adrenolytic activity, trazodone capsules has very rarely been associated with priapism. This may be treated with an intracavernosum injection of an alpha-adrenergic agent such as adrenaline or metaraminol. However, there are reports of trazodone -induced priapism which have required surgical intervention or led to permanent sexual dysfunction. Patients developing this suspected adverse reaction should cease trazodone capsules immediately. Excipients Trazodone capsules contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Trazodone capsules contains carmoisine. May cause allergic reactions. Information on sodium content This medicine contains less than 1 mmol sodium (23 mg) per capsule, i.e. is essentially 'sodium-free'.4.5 Interaction with other medicinal products and other forms of interaction General The sedative effects of antipsychotics, hypnotics, sedatives, anxiolytics, and antihistaminic drugs may be intensified; dosage reduction is recommended in such instances. The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives, phenytoin, carbamazepine and barbiturates. The metabolism of antidepressants is inhibited by cimetidine and some other antipsychotics. CYP3A4 inhibitors In vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with potent CYP3A4 inhibitors such as erythromycin, ketoconazole, itraconazole, ritonavir, indinavir, and nefazodone. It is likely that potent CYP3A4 inhibitors may lead to substantial increases in trazodone plasma concentrations with the potential for adverse effects. Exposure to ritonavir during initiation or resumption of treatment in patients receiving trazodone will increase the potential for excessive sedation, cardiovascular, and gastrointestinal effects. It has been confirmed in \*in-vivo\* studies in healthy volunteers that a ritonavir dose of 200 mg BID increased the plasma levels of trazodone by greater than two-fold, leading to nausea, syncope and hypotension. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered. However, the co- administration of trazodone and potent CYP3A4 inhibitors should be avoided where possible. Carbamazepine Carbamazepine reduced plasma concentrations of trazodone when co-administered. Concomitant use of carbamazepine 400 mg daily led to a decrease of plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine of 76% and 60%, respectively. Patients should be closely monitored to see if there is a need for an increased dose of trazodone capsules when taken with carbamazepine. Trazodone should be used cautiously when co-administered with: • \*\*Buprenorphine/opioids as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).\*\* Muscle relaxants, volatile anaesthetics, sedative and anti-depressant drugs, alcohol Trazodone capsules may enhance the effects of muscle relaxants and volatile anaesthetics, and caution should be exercised in such instances. Similar considerations apply to combined administration with sedative and anti-depressant drugs, including alcohol. Trazodone intensifies the sedative effects of alcohol. Alcohol should be avoided during trazodone therapy. Trazodone capsules have been well tolerated in depressed schizophrenic patients receiving standard phenothiazine therapy and also in depressed parkinsonian patients receiving therapy with levodopa. Anti-depressants can accelerate the metabolism of levodopa. Tricyclic antidepressants Concurrent administration should be avoided due to the risk of interaction. Serotonin syndrome and cardiovascular side effects are possible. Fluoxetine Rare cases have been reported of elevated trazodone plasma levels and adverse effects when trazodone had been combined with fluoxetine, a CYP1A2/2D6 inhibitor. The mechanism underlying a pharmacokinetic interaction is not fully understood. A pharmacodynamic interaction (serotonin syndrome) could not be excluded. MonoAmine Oxidase Inhibitors Possible interactions with monoamine oxidase inhibitors have occasionally been reported. Although some clinicians do give both concurrently, use of trazodone capsules with MAOIs, or within two weeks of stopping treatment with these compounds is not recommended. The giving of MAOIs within one week of stopping trazodone capsules is also not recommended. Phenothiazines Severe orthostatic hypotension has been observed in case of concomitant use of phenothiazines, such as chlorpromazine, fluphenazine, levomepromazine, and perphenazine. Medicines causing QT prolongation Concomitant use of trazodone capsules with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Caution should be used when these drugs are co-administered with trazodone capsules. Other cardiac medicines Since trazodone is only a very weak inhibitor of noradrenaline re-uptake and does not modify the blood pressure response to tyramine, interference with the hypotensive action of guanethidine-like compounds is unlikely. However, studies in laboratory animals suggest that trazodone may inhibit most of the acute actions of clonidine. In the case of other types of antihypertensive drugs, although no clinical interactions have been reported, the possibility of potentiation should be considered. St John's Wort Undesirable effects may be more frequent when trazodone capsules are administered together with preparations containing \*Hypericum perforatum\* (St John's Wort). Warfarin There have been reports of changes in prothrombin time in patients concomitantly receiving trazodone and warfarin. Digoxin and phenytoin Concurrent use with trazodone capsules may result in elevated serum levels of digoxin or phenytoin. Monitoring of serum levels should be considered in these patients.4.6 Fertility, pregnancy and lactation Pregnancy Data on a limited number (< 200) of exposed pregnancies indicate no adverse effects of trazodone on pregnancy or on the health of the foetus/new-born child. To date, no other relevant epidemiological data are available. The safety of trazodone in human pregnancy has not been established. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development at therapeutic doses. On basic principles, therefore, its use during the first trimester should be avoided. Caution should be exercised when prescribing to pregnant women. When trazodone is used until delivery, new-borns should be monitored for the occurrence of withdrawal symptoms. Breast-feeding Limited data indicate that excretion of trazodone in human breast milk is low, but levels of the active metabolite are not known. Due to the paucity of data, a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with trazodone capsules should be made taking into account the benefit of breast-feeding to the child and the benefit of trazodone therapy to the woman. Fertility No human data on the effect of active substance trazodone on fertility are available.4.7 Effects on ability to drive and use machines Trazodone has minor or moderate influence on the ability to drive and use machines. As with all other drugs acting on the central nervous system, patients should be cautioned against the risks of driving or operating machinery until they are sure they are not affected by drowsiness, sedation, dizziness, confusional states, or blurred vision.4.8 Undesirable effects Cases of suicidal ideation and suicidal behaviours have been reported during trazodone therapy or early after treatment discontinuation (see section 4.4). Trazodone capsules has had no effect on arterial blood pCO2 or pO2 levels in patients with severe respiratory insufficiency due to chronic bronchial or pulmonary disease. The following symptoms, some of which are commonly reported in cases of untreated depression, have also been recorded in patients receiving trazodone therapy. | | | | --- | --- | | \*\*MedDRA System Organ Class\*\* | \*\*Frequency not known (cannot be estimated from the available data)\*\* | | Blood and lymphatic system disorders | Blood dyscrasias (including agranulocytosis, thrombocytopenia, eosinophilia, leucopenia and anaemia) | | Immune system disorders | Allergic reactions | | Endocrine disorders | Syndrome of Inappropriate Antidiuretic Hormone Secretion | | Metabolism and nutrition disorders | Hyponatraemia1, weight loss, anorexia, increased appetite | | Psychiatric disorders | Suicidal ideation or suicidal behaviours2, confusional state, insomnia, disorientation, mania, anxiety, nervousness, agitation (very occasionally exacerbating to delirium), delusion, aggressive reaction, hallucinations, nightmares, libido decreased, withdrawal syndrome | | Nervous system disorders | Serotonin syndrome, convulsion, neuroleptic malignant syndrome, dizziness, vertigo, headache, drowsiness3, restlessness, decreased alertness, tremor, blurred vision, memory disturbance, myoclonus, expressive aphasia, paraesthesia, dystonia, taste altered | | Cardiac disorders | Cardiac arrhythmias4 (including Torsade de Pointes, palpitations, premature ventricular contractions, ventricular couplets, ventricular tachycardia), bradycardia, tachycardia, ECG abnormalities (QT prolongation)2 | | Vascular disorders | Orthostatic hypotension, hypertension, syncope | | Respiratory, thoracic and mediastinal disorders | Nasal congestion, dyspnoea | | Gastrointestinal disorders | Nausea, vomiting, dry mouth, constipation, diarrhoea, dyspepsia, stomach pain, gastroenteritis, increased salivation, paralytic ileus | | Hepato-biliary disorders | Hepatic function abnormalities (including jaundice and hepatocellular damage)5, cholestasis intrahepatic, severe hepatic disorders such as hepatitis/fulminant hepatitis, hepatic failure with potential fatal outcome | | Skin and subcutaneous tissue disorders | Skin rash, pruritus, hyperhidrosis | | Musculoskeletal and connective tissue disorders | Pain in limb, back pain, myalgia, arthralgia | | Renal and urinary disorders | Micturition disorder | | Reproductive system and breast disorders | Priapism6 | | General disorders and administration site conditions | Weakness, oedema, influenza-like symptoms, fatigue, chest pain, fever | | Investigations | Elevated liver enzymes | 1 Fluid and electrolyte status should be monitored in symptomatic patients. 2 See also Section 4.4. 3 Trazodone is a sedative antidepressant and drowsiness, sometimes experienced during the first days of treatment, usually disappears on continued therapy. 4 Studies in animals have shown that trazodone is less cardiotoxic than the tricyclic antidepressants, and clinical studies suggest that the drug may be less likely to cause cardiac arrhythmias in man. Clinical studies in patients with pre-existing cardiac disease indicate that trazodone may be arrhythmogenic in some patients in that population. 5 Adverse effects on hepatic function, sometimes severe, have been rarely reported. Should such effects occur, trazodone should be immediately discontinued. 6 See also section 4.4. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose Features of toxicity The most frequently reported reactions to overdose have included drowsiness, dizziness, nausea and vomiting. In more serious cases coma, tachycardia, hypotension, hyponatraemia, convulsions and respiratory failure have been reported. Cardiac features may include bradycardia, QT prolongation and torsade de pointes. Symptoms may appear 24 hours or more after overdose. Overdoses of trazodone capsules in combination with other antidepressants may cause serotonin syndrome. Management There is no specific antidote to trazodone. Activated charcoal should be considered in adults who have ingested more than 1 g trazodone, or in children who have ingested more than 150 mg trazodone within 1 hour of presentation. Alternatively, in adults, gastric lavage may be considered within 1 hour of ingestion of a potentially life-threatening overdose. Observe for at least 6 hours after ingestion (or 12 hours if a sustained release preparation has been taken). Monitor BP, pulse and Glasgow Coma Scale (GCS). Monitor oxygen saturation if GCS is reduced. Cardiac monitoring is appropriate in symptomatic patients. Single brief convulsions do not require treatment. Control frequent or prolonged convulsions with intravenous diazepam (0.1 to 0.3 mg/kg body weight) or lorazepam (4 mg in an adult and 0.05 mg/kg in a child). If these measures do not control the fits, an intravenous infusion of phenytoin may be useful. Give oxygen and correct acid base and metabolic disturbances as required. Treatment should be symptomatic and supportive in the case of hypotension and excessive sedation. If severe hypotension persists consider use of inotropes, e.g., dopamine or dobutamine.
Instruction Pharmacology: 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Other anti-depressants, ATC code: N06A X05 Trazodone is a potent anti-depressant. It also has anxiety reducing activity. Trazodone is a triazolopyridine derivative chemically unrelated to known tricyclic, tetracyclic and other anti- depressant agents. It has a negligible effect on noradrenaline re-uptake mechanisms. Mechanism of action Whilst the mode of action of trazodone is not known precisely, its anti-depressant activity may concern noradrenergic potentiation by mechanisms other than uptake blockade. A central anti- serotonin effect may account for the drug's anxiety reducing properties.5.2 Pharmacokinetic properties Absorption Trazodone is rapidly absorbed from the gastro-intestinal tract and extensively metabolised. Biotransformation Paths of metabolism of trazodone include n-oxidation and hydroxylation. The metabolic m- chlorophenylpiperazine is active. \*In vitro\* studies in human liver microsomes show that trazodone is metabolised by cytochrome P4503A4 (CYP3A4) to form m-chlorophenylpiperazine. Whilst significant, the role of this pathway in the total clearance of trazodone \*in vivo\* has not been fully determined. Elimination Trazodone is excreted in the urine almost entirely in the form of its metabolites, either in free or in conjugated form. The elimination of trazodone is biphasic, with a terminal elimination half-life of 5 to 13 hours. Trazodone is excreted in breast milk. Pharmacokinetic/pharmacodynamic relationship(s) There was an approximate two-fold increase in terminal phase half-life and significantly higher plasma concentrations of trazodone in 10 subjects aged 65 to 74 years compared with 12 subjects aged 23 to 30 years following a 100 mg dose of trazodone. It was suggested that there is an age-related reduction in the hepatic metabolism of trazodone.5.3 Preclinical safety data Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, carcinogenic potential, toxicity to reproduction and development.
Instruction Pharmaceutical Particulars: 6.1 List of excipients Capsule content Lactose monohydrate Magnesium stearate Capsule shell \*Cap\* Gelatin Titanium dioxide (E171) Carmoisine (E122) Patent blue V (E131) \*Body\* Gelatin Titanium dioxide (E171) Iron oxide yellow (E172) Patent blue V (E131) Carmoisine (E122) \*Printing ink (TekPrink SW-9008 & ACG PAM BKI004)\* Shellac (E904) Propylene glycol (E1520) Black iron oxide (E172) Potassium hydroxide (E525)6.2 Incompatibilities Not applicable.6.3 Shelf life 2 years6.4 Special precautions for storage This medicinal product does not require any special storage conditions.6.5 Nature and contents of container Blister pack - Alu/ PVC/PVDC Blister packs of 20, 28, 30, 56, 84, 90, 100, 112, 120, 168 and 180 capsules. Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Instruction Content: ## Composition Each capsule, hard contains 50 mg trazodone hydrochloride. Excipients with known effect Each capsule, hard contains 73.75 mg of lactose monohydrate. Each capsule, hard contains 0.0094 mg of carmoisine. For the full list of excipients, see section 6.1. ## Pharmaceutical Form Capsule, hard (capsule) White to off white granular powder filled in size “3” hard gelatin capsule with violet color cap and green color body printed 'TZ' on cap and '50' on body in black. ## Clinical Particulars 4.1 Therapeutic indications Anxiety, depression, mixed anxiety and depression.4.2 Posology and method of administration Posology Depression \*Adults\* Initially 150 mg/day in divided doses after food or as a single dose on retiring. This may be increased up to 300 mg/day in a single or divided doses. The major portion of a divided dose to be taken on retiring. The dose may be further increased to 600 mg/day in divided doses in hospitalised patients. \*Elderly\* For very elderly or frail patients, the recommended initial starting dose is reduced to 100 mg/day given in divided doses or as a single night-time dose (see section 4.4). This may be incrementally increased, under supervision, according to efficacy and tolerance. In general, single doses above 100 mg should be avoided in these patients. It is unlikely that 300 mg/day will be exceeded. \*Paediatric population\* There are insufficient data on safety to recommend the use of trazodone capsules in children below the age of 18 years. Depression accompanied by anxiety As for depression Anxiety 75 mg/day increasing to 300 mg/day as necessary. \*Hepatic Impairment\* Trazodone undergoes extensive hepatic metabolism, see section 5.2, and has also been associated with hepatotoxicity, see sections 4.4 and 4.8. Therefore caution should be exercised when prescribing for patients with hepatic impairment, particularly in cases of severe hepatic impairment. Periodic monitoring of liver function may be considered. \*Renal Impairment\* No dosage adjustment is usually necessary, but caution should be exercised when prescribing for patients with severe renal impairment (see also section 4.4 and 5.2). Method of administration For oral use. A decrease in side-effects (increase of the resorption and decrease of the peak plasma concentration) can be reached by taking trazodone capsules after a meal.4.3 Contraindications • Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. • Alcohol intoxication and intoxication with hypnotics. • Acute myocardial infarction.4.4 Special warnings and precautions for use Paediatric population Trazodone capsules should not be used in children and adolescents under 18 years old. Suicidal behaviour (suicidal attempt and suicidal planning) and hostility (essentially aggressiveness, opposing behaviour and anger) has been observed in a clinical study on children and adolescents treated with antidepressant more frequently than with placebo. Moreover, long-term safety data on children and adolescents regarding growth, maturation and cognitive and behavioural development are not available. Suicide/suicidal thoughts or clinical worsening Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide- related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Other psychiatric conditions for which trazodone capsules is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders. Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo- controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present. To minimise the potential risk of suicide attempts, particularly at therapy initiation, only restricted quantities of trazodone capsules should be prescribed at each occasion. It is recommended that careful dosing and regular monitoring is adopted in patients with the following conditions: • Epilepsy, specifically abrupt increases or decreases of dosage should be avoided. • Patients with hepatic or renal impairment, particularly if severe. • Patients with cardiac disease, such as angina pectoris, conduction disorders or AV blocks of different degree, recent myocardial infarction. • Hyperthyroidism. • Micturition disorders, such as prostate hypertrophy, although problems would not be anticipated as the anticholinergic effect of trazodone capsules is only minor. • Acute narrow angle glaucoma, raised intra-ocular pressure, although major changes would not be anticipated due to the minor anticholinergic effect of trazodone capsules. Should jaundice occur in a patient, trazodone therapy must be withdrawn. Hepatic disorders Severe hepatic disorders with potential fatal outcome have been reported with trazodone use (see adverse reaction section). Patients should be instructed to immediately report signs such as asthenia, anorexia, nausea, vomiting, abdominal pain or icterus to a physician. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately, and withdrawal of trazodone therapy be considered. Schizophrenia and other psychotic disorders Administration of antidepressants in patients with schizophrenia or other psychotic disorders may result in a possible worsening of psychotic symptoms. Paranoid thoughts may be intensified. During trazodone therapy a depressive phase can change from a manic–depressive psychosis into a manic phase. In that case trazodone capsules must be stopped. Serotonin Syndrome / Malignant Neuroleptic Syndrome Interactions in terms of serotonin syndrome/malignant neuroleptic syndrome have been described in case of concomitant use of other serotonergically acting substances like other antidepressants (e.g., tricyclic antidepressants, SSRIs, SNRIs and MAO-inhibitors) and neuroleptics. Malignant neuroleptic syndromes with fatal outcome have been reported in cases of co-administration with neuroleptics, for which this syndrome is a known possible adverse drug reaction. See sections 4.5 and 4.8 for further information. \*Serotonin syndrome\* Concomitant administration of trazodone and \*\*buprenorphine/opioids may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5).\*\* If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms. Agranulocytosis Since agranulocytosis may clinically reveal itself with influenza-like symptoms, sore throat, and fever, in these cases it is recommended to check haematology. Hypotension Hypotension, including orthostatic hypotension and syncope, has been reported to occur in patients receiving trazodone capsules. Concomitant administration of antihypertensive therapy with trazodone capsules may require a reduction in the dose of the antihypertensive drug. Elderly population Elderly patients may more often experience orthostatic hypotension, somnolence and other anticholinergic effects of trazodone. Careful consideration should be given to the potential for additive effects with concomitant medication use such as with other psychotropics or antihypertensives or in the presence of risk factors such as comorbid disease, which may exacerbate these reactions. It is recommended that the patient/carer be informed of the potential for these reactions and monitored closely for such effects following initiation of therapy, prior to and following upward dose titration. Withdrawal symptoms Following trazodone therapy, particularly for a prolonged period, an incremental dosage reduction to withdrawal is recommended, to minimise the occurrence of withdrawal symptoms, characterised by nausea, headache, and malaise. There is no evidence that trazodone capsules possesses any addictive properties. QT prolongation As with other antidepressant drugs, cases of QT interval prolongation have been reported with trazodone capsules very rarely. Caution is advised when prescribing trazodone capsules with medicinal products known to prolong QT interval. Trazodone capsules should be used with caution in patients with known cardiovascular disease including those associated with prolongation of the QT interval. CYP3A4 inhibitors Potent CYP3A4 inhibitors may lead to increases in trazodone serum levels. See section 4.5 for further information. Priapism As with other drugs with alpha-adrenolytic activity, trazodone capsules has very rarely been associated with priapism. This may be treated with an intracavernosum injection of an alpha-adrenergic agent such as adrenaline or metaraminol. However, there are reports of trazodone -induced priapism which have required surgical intervention or led to permanent sexual dysfunction. Patients developing this suspected adverse reaction should cease trazodone capsules immediately. Excipients Trazodone capsules contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Trazodone capsules contains carmoisine. May cause allergic reactions. Information on sodium content This medicine contains less than 1 mmol sodium (23 mg) per capsule, i.e. is essentially 'sodium-free'.4.5 Interaction with other medicinal products and other forms of interaction General The sedative effects of antipsychotics, hypnotics, sedatives, anxiolytics, and antihistaminic drugs may be intensified; dosage reduction is recommended in such instances. The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives, phenytoin, carbamazepine and barbiturates. The metabolism of antidepressants is inhibited by cimetidine and some other antipsychotics. CYP3A4 inhibitors In vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with potent CYP3A4 inhibitors such as erythromycin, ketoconazole, itraconazole, ritonavir, indinavir, and nefazodone. It is likely that potent CYP3A4 inhibitors may lead to substantial increases in trazodone plasma concentrations with the potential for adverse effects. Exposure to ritonavir during initiation or resumption of treatment in patients receiving trazodone will increase the potential for excessive sedation, cardiovascular, and gastrointestinal effects. It has been confirmed in \*in-vivo\* studies in healthy volunteers that a ritonavir dose of 200 mg BID increased the plasma levels of trazodone by greater than two-fold, leading to nausea, syncope and hypotension. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered. However, the co- administration of trazodone and potent CYP3A4 inhibitors should be avoided where possible. Carbamazepine Carbamazepine reduced plasma concentrations of trazodone when co-administered. Concomitant use of carbamazepine 400 mg daily led to a decrease of plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine of 76% and 60%, respectively. Patients should be closely monitored to see if there is a need for an increased dose of trazodone capsules when taken with carbamazepine. Trazodone should be used cautiously when co-administered with: • \*\*Buprenorphine/opioids as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).\*\* Muscle relaxants, volatile anaesthetics, sedative and anti-depressant drugs, alcohol Trazodone capsules may enhance the effects of muscle relaxants and volatile anaesthetics, and caution should be exercised in such instances. Similar considerations apply to combined administration with sedative and anti-depressant drugs, including alcohol. Trazodone intensifies the sedative effects of alcohol. Alcohol should be avoided during trazodone therapy. Trazodone capsules have been well tolerated in depressed schizophrenic patients receiving standard phenothiazine therapy and also in depressed parkinsonian patients receiving therapy with levodopa. Anti-depressants can accelerate the metabolism of levodopa. Tricyclic antidepressants Concurrent administration should be avoided due to the risk of interaction. Serotonin syndrome and cardiovascular side effects are possible. Fluoxetine Rare cases have been reported of elevated trazodone plasma levels and adverse effects when trazodone had been combined with fluoxetine, a CYP1A2/2D6 inhibitor. The mechanism underlying a pharmacokinetic interaction is not fully understood. A pharmacodynamic interaction (serotonin syndrome) could not be excluded. MonoAmine Oxidase Inhibitors Possible interactions with monoamine oxidase inhibitors have occasionally been reported. Although some clinicians do give both concurrently, use of trazodone capsules with MAOIs, or within two weeks of stopping treatment with these compounds is not recommended. The giving of MAOIs within one week of stopping trazodone capsules is also not recommended. Phenothiazines Severe orthostatic hypotension has been observed in case of concomitant use of phenothiazines, such as chlorpromazine, fluphenazine, levomepromazine, and perphenazine. Medicines causing QT prolongation Concomitant use of trazodone capsules with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Caution should be used when these drugs are co-administered with trazodone capsules. Other cardiac medicines Since trazodone is only a very weak inhibitor of noradrenaline re-uptake and does not modify the blood pressure response to tyramine, interference with the hypotensive action of guanethidine-like compounds is unlikely. However, studies in laboratory animals suggest that trazodone may inhibit most of the acute actions of clonidine. In the case of other types of antihypertensive drugs, although no clinical interactions have been reported, the possibility of potentiation should be considered. St John's Wort Undesirable effects may be more frequent when trazodone capsules are administered together with preparations containing \*Hypericum perforatum\* (St John's Wort). Warfarin There have been reports of changes in prothrombin time in patients concomitantly receiving trazodone and warfarin. Digoxin and phenytoin Concurrent use with trazodone capsules may result in elevated serum levels of digoxin or phenytoin. Monitoring of serum levels should be considered in these patients.4.6 Fertility, pregnancy and lactation Pregnancy Data on a limited number (< 200) of exposed pregnancies indicate no adverse effects of trazodone on pregnancy or on the health of the foetus/new-born child. To date, no other relevant epidemiological data are available. The safety of trazodone in human pregnancy has not been established. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development at therapeutic doses. On basic principles, therefore, its use during the first trimester should be avoided. Caution should be exercised when prescribing to pregnant women. When trazodone is used until delivery, new-borns should be monitored for the occurrence of withdrawal symptoms. Breast-feeding Limited data indicate that excretion of trazodone in human breast milk is low, but levels of the active metabolite are not known. Due to the paucity of data, a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with trazodone capsules should be made taking into account the benefit of breast-feeding to the child and the benefit of trazodone therapy to the woman. Fertility No human data on the effect of active substance trazodone on fertility are available.4.7 Effects on ability to drive and use machines Trazodone has minor or moderate influence on the ability to drive and use machines. As with all other drugs acting on the central nervous system, patients should be cautioned against the risks of driving or operating machinery until they are sure they are not affected by drowsiness, sedation, dizziness, confusional states, or blurred vision.4.8 Undesirable effects Cases of suicidal ideation and suicidal behaviours have been reported during trazodone therapy or early after treatment discontinuation (see section 4.4). Trazodone capsules has had no effect on arterial blood pCO2 or pO2 levels in patients with severe respiratory insufficiency due to chronic bronchial or pulmonary disease. The following symptoms, some of which are commonly reported in cases of untreated depression, have also been recorded in patients receiving trazodone therapy. | | | | --- | --- | | \*\*MedDRA System Organ Class\*\* | \*\*Frequency not known (cannot be estimated from the available data)\*\* | | Blood and lymphatic system disorders | Blood dyscrasias (including agranulocytosis, thrombocytopenia, eosinophilia, leucopenia and anaemia) | | Immune system disorders | Allergic reactions | | Endocrine disorders | Syndrome of Inappropriate Antidiuretic Hormone Secretion | | Metabolism and nutrition disorders | Hyponatraemia1, weight loss, anorexia, increased appetite | | Psychiatric disorders | Suicidal ideation or suicidal behaviours2, confusional state, insomnia, disorientation, mania, anxiety, nervousness, agitation (very occasionally exacerbating to delirium), delusion, aggressive reaction, hallucinations, nightmares, libido decreased, withdrawal syndrome | | Nervous system disorders | Serotonin syndrome, convulsion, neuroleptic malignant syndrome, dizziness, vertigo, headache, drowsiness3, restlessness, decreased alertness, tremor, blurred vision, memory disturbance, myoclonus, expressive aphasia, paraesthesia, dystonia, taste altered | | Cardiac disorders | Cardiac arrhythmias4 (including Torsade de Pointes, palpitations, premature ventricular contractions, ventricular couplets, ventricular tachycardia), bradycardia, tachycardia, ECG abnormalities (QT prolongation)2 | | Vascular disorders | Orthostatic hypotension, hypertension, syncope | | Respiratory, thoracic and mediastinal disorders | Nasal congestion, dyspnoea | | Gastrointestinal disorders | Nausea, vomiting, dry mouth, constipation, diarrhoea, dyspepsia, stomach pain, gastroenteritis, increased salivation, paralytic ileus | | Hepato-biliary disorders | Hepatic function abnormalities (including jaundice and hepatocellular damage)5, cholestasis intrahepatic, severe hepatic disorders such as hepatitis/fulminant hepatitis, hepatic failure with potential fatal outcome | | Skin and subcutaneous tissue disorders | Skin rash, pruritus, hyperhidrosis | | Musculoskeletal and connective tissue disorders | Pain in limb, back pain, myalgia, arthralgia | | Renal and urinary disorders | Micturition disorder | | Reproductive system and breast disorders | Priapism6 | | General disorders and administration site conditions | Weakness, oedema, influenza-like symptoms, fatigue, chest pain, fever | | Investigations | Elevated liver enzymes | 1 Fluid and electrolyte status should be monitored in symptomatic patients. 2 See also Section 4.4. 3 Trazodone is a sedative antidepressant and drowsiness, sometimes experienced during the first days of treatment, usually disappears on continued therapy. 4 Studies in animals have shown that trazodone is less cardiotoxic than the tricyclic antidepressants, and clinical studies suggest that the drug may be less likely to cause cardiac arrhythmias in man. Clinical studies in patients with pre-existing cardiac disease indicate that trazodone may be arrhythmogenic in some patients in that population. 5 Adverse effects on hepatic function, sometimes severe, have been rarely reported. Should such effects occur, trazodone should be immediately discontinued. 6 See also section 4.4. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose Features of toxicity The most frequently reported reactions to overdose have included drowsiness, dizziness, nausea and vomiting. In more serious cases coma, tachycardia, hypotension, hyponatraemia, convulsions and respiratory failure have been reported. Cardiac features may include bradycardia, QT prolongation and torsade de pointes. Symptoms may appear 24 hours or more after overdose. Overdoses of trazodone capsules in combination with other antidepressants may cause serotonin syndrome. Management There is no specific antidote to trazodone. Activated charcoal should be considered in adults who have ingested more than 1 g trazodone, or in children who have ingested more than 150 mg trazodone within 1 hour of presentation. Alternatively, in adults, gastric lavage may be considered within 1 hour of ingestion of a potentially life-threatening overdose. Observe for at least 6 hours after ingestion (or 12 hours if a sustained release preparation has been taken). Monitor BP, pulse and Glasgow Coma Scale (GCS). Monitor oxygen saturation if GCS is reduced. Cardiac monitoring is appropriate in symptomatic patients. Single brief convulsions do not require treatment. Control frequent or prolonged convulsions with intravenous diazepam (0.1 to 0.3 mg/kg body weight) or lorazepam (4 mg in an adult and 0.05 mg/kg in a child). If these measures do not control the fits, an intravenous infusion of phenytoin may be useful. Give oxygen and correct acid base and metabolic disturbances as required. Treatment should be symptomatic and supportive in the case of hypotension and excessive sedation. If severe hypotension persists consider use of inotropes, e.g., dopamine or dobutamine. ## Pharmacological Properties 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Other anti-depressants, ATC code: N06A X05 Trazodone is a potent anti-depressant. It also has anxiety reducing activity. Trazodone is a triazolopyridine derivative chemically unrelated to known tricyclic, tetracyclic and other anti- depressant agents. It has a negligible effect on noradrenaline re-uptake mechanisms. Mechanism of action Whilst the mode of action of trazodone is not known precisely, its anti-depressant activity may concern noradrenergic potentiation by mechanisms other than uptake blockade. A central anti- serotonin effect may account for the drug's anxiety reducing properties.5.2 Pharmacokinetic properties Absorption Trazodone is rapidly absorbed from the gastro-intestinal tract and extensively metabolised. Biotransformation Paths of metabolism of trazodone include n-oxidation and hydroxylation. The metabolic m- chlorophenylpiperazine is active. \*In vitro\* studies in human liver microsomes show that trazodone is metabolised by cytochrome P4503A4 (CYP3A4) to form m-chlorophenylpiperazine. Whilst significant, the role of this pathway in the total clearance of trazodone \*in vivo\* has not been fully determined. Elimination Trazodone is excreted in the urine almost entirely in the form of its metabolites, either in free or in conjugated form. The elimination of trazodone is biphasic, with a terminal elimination half-life of 5 to 13 hours. Trazodone is excreted in breast milk. Pharmacokinetic/pharmacodynamic relationship(s) There was an approximate two-fold increase in terminal phase half-life and significantly higher plasma concentrations of trazodone in 10 subjects aged 65 to 74 years compared with 12 subjects aged 23 to 30 years following a 100 mg dose of trazodone. It was suggested that there is an age-related reduction in the hepatic metabolism of trazodone.5.3 Preclinical safety data Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, carcinogenic potential, toxicity to reproduction and development. ## Pharmaceutical Particulars 6.1 List of excipients Capsule content Lactose monohydrate Magnesium stearate Capsule shell \*Cap\* Gelatin Titanium dioxide (E171) Carmoisine (E122) Patent blue V (E131) \*Body\* Gelatin Titanium dioxide (E171) Iron oxide yellow (E172) Patent blue V (E131) Carmoisine (E122) \*Printing ink (TekPrink SW-9008 & ACG PAM BKI004)\* Shellac (E904) Propylene glycol (E1520) Black iron oxide (E172) Potassium hydroxide (E525)6.2 Incompatibilities Not applicable.6.3 Shelf life 2 years6.4 Special precautions for storage This medicinal product does not require any special storage conditions.6.5 Nature and contents of container Blister pack - Alu/ PVC/PVDC Blister packs of 20, 28, 30, 56, 84, 90, 100, 112, 120, 168 and 180 capsules. Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Active Ingredients

Approved

Quick Info

Agency

UK EMC

Country

🇬🇧

Approval ID

57b87cd547aa01a5

Type

Standard

Back to UK EMC Approvals